Revisiting Interleukin-12 as a Cancer Immunotherapy Agent

作者：Pedro Berraondo, Iñaki Etxeberría, Mariano Ponz‐Sarvisé, Ignacio Melero · 发表于：Clinical Cancer Research · 年份：2018 · DOI：10.1158/1078-0432.ccr-18-0381 · 被引用次数：95 · 研究领域：CAR-T cell therapy research、Immune Cell Function and Interaction、Virus-based gene therapy research

Abstract IL12 antitumor activities are mediated by the activation of T and natural killer (NK) lymphocytes to produce IFNγ. Systemically, recombinant IL12 has a narrow therapeutic window that favors local delivery, for instance, by gene therapy approaches. IL12 is a powerful partner in immunotherapy combinations with checkpoint inhibitors and adoptive T-cell transfer. Clin Cancer Res; 24(12); 2716–8. ©2018 AACR. See related article by Hu et al., p. 2920